Erste Asset Management GmbH bought a new position in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) during the third quarter, according to its most recent filing with the SEC. The firm bought 15,000 shares of the company's stock, valued at approximately $741,000.
A number of other large investors also recently modified their holdings of the company. Vanguard Group Inc. raised its position in MoonLake Immunotherapeutics by 25.3% in the 1st quarter. Vanguard Group Inc. now owns 92,298 shares of the company's stock valued at $4,636,000 after buying an additional 18,641 shares during the last quarter. Victory Capital Management Inc. raised its position in MoonLake Immunotherapeutics by 16.0% in the 2nd quarter. Victory Capital Management Inc. now owns 174,682 shares of the company's stock valued at $7,681,000 after buying an additional 24,037 shares during the last quarter. Rice Hall James & Associates LLC purchased a new stake in MoonLake Immunotherapeutics in the 3rd quarter valued at $3,805,000. Harbor Capital Advisors Inc. raised its position in MoonLake Immunotherapeutics by 100.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 77,468 shares of the company's stock valued at $3,906,000 after buying an additional 38,779 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its position in MoonLake Immunotherapeutics by 37.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 114,234 shares of the company's stock valued at $5,023,000 after buying an additional 31,401 shares during the last quarter. 93.85% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
A number of research firms recently commented on MLTX. Needham & Company LLC reissued a "buy" rating and issued a $62.00 price target on shares of MoonLake Immunotherapeutics in a research report on Thursday, September 12th. Wedbush reaffirmed an "outperform" rating and set a $73.00 target price (down from $92.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, November 5th. Wolfe Research lowered MoonLake Immunotherapeutics from an "outperform" rating to a "peer perform" rating in a research report on Monday, August 26th. HC Wainwright reaffirmed a "buy" rating and set a $100.00 target price on shares of MoonLake Immunotherapeutics in a research report on Thursday, November 14th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of MoonLake Immunotherapeutics in a research report on Monday, September 23rd. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, MoonLake Immunotherapeutics has an average rating of "Moderate Buy" and an average target price of $79.00.
View Our Latest Research Report on MoonLake Immunotherapeutics
MoonLake Immunotherapeutics Price Performance
MLTX stock traded up $1.76 during midday trading on Wednesday, hitting $53.06. The stock had a trading volume of 132,446 shares, compared to its average volume of 364,338. The firm has a market cap of $3.39 billion, a price-to-earnings ratio of -39.77 and a beta of 1.31. The business has a 50-day moving average of $50.21 and a two-hundred day moving average of $46.65. MoonLake Immunotherapeutics has a 52-week low of $37.55 and a 52-week high of $64.98.
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.12). During the same period in the previous year, the firm earned ($0.18) earnings per share. Research analysts predict that MoonLake Immunotherapeutics will post -1.74 earnings per share for the current year.
Insider Activity at MoonLake Immunotherapeutics
In related news, Director Simon Sturge sold 171,000 shares of MoonLake Immunotherapeutics stock in a transaction that occurred on Friday, October 4th. The stock was sold at an average price of $53.72, for a total transaction of $9,186,120.00. Following the sale, the director now owns 171,980 shares of the company's stock, valued at approximately $9,238,765.60. This trade represents a 49.86 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 12.02% of the stock is currently owned by insiders.
About MoonLake Immunotherapeutics
(
Free Report)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
See Also
Before you consider MoonLake Immunotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MoonLake Immunotherapeutics wasn't on the list.
While MoonLake Immunotherapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
